Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma - Full Text View

Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. Combining these therapies may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy and radiation therapy with or without peripheral stem cell transplantation in treating patients who have neuroblastoma.

Condition	Intervention	Phase
Neuroblastoma	Drug: carboplatin Drug: cisplatin Drug: cyclophosphamide Drug: dacarbazine Drug: doxorubicin hydrochloride Drug: etoposide Drug: filgrastim Drug: ifosfamide Drug: melphalan Drug: tretinoin Drug: vincristine sulfate Drug: vindesine Procedure: autologous bone marrow transplantation Procedure: conventional surgery Procedure: peripheral blood stem cell transplantation Procedure: radiation therapy	Phase II

MedlinePlus related topics:

Bone Marrow Transplantation Cancer Neuroblastoma

Drug Information available for:

Doxorubicin Doxorubicin hydrochloride Ifosfamide Cyclophosphamide Carboplatin Filgrastim Etoposide Cisplatin Melphalan Vincristine sulfate Vincristine Dacarbazine Etoposide phosphate Tretinoin Melphalan hydrochloride Sarcolysin Vindesine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Official Title:	Neuroblastoma Study Phase II Study of Various Therapies in Patients With Neuroblastoma

Further study details as provided by National Cancer Institute (NCI):

Study Start Date:

May 1997

Show Detailed Description

Eligibility

Ages Eligible for Study:	up to 20 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Histologically confirmed neuroblastoma
Observation stratum:
- MYCN gene not amplified
- Infants with stage I-IVS disease OR
- Over 1 year of age and stage I or II resectable disease
Standard-risk stratum:
- MYCN gene not amplified
- Infants with serious symptoms and stage II-IVS disease OR
- Over 1 year of age with stage II or III unresectable disease
High-risk stratum:
- Stage IV disease OR
- Stage I-IVS MYCN gene-amplified disease

PATIENT CHARACTERISTICS:

Age:

20 and under

Performance status:

Not specified

Life expectancy:

Not specified

Hematopoietic:

Not specified

Hepatic:

Not specified

Renal:

No kidney insufficiency

Cardiovascular:

No cardiac insufficiency

Other:

Not pregnant
Fertile patients must use effective contraception
No other serious illness

PRIOR CONCURRENT THERAPY:

Biologic therapy:

Not specified

Chemotherapy:

No prior chemotherapy within 6 months after diagnosis

Endocrine therapy:

Not specified

Radiotherapy:

Not specified

Surgery:

Not specified

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00017225

Show 94 Study Locations

Sponsors and Collaborators

Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany

Investigators


Study Chair:	Frank Berthold, MD	Children's Hospital

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

Publications of Results:

Simon T, Hero B, Bongartz R, Schmidt M, Muller RP, Berthold F. Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease. Strahlenther Onkol. 2006 Jul;182(7):389-94.

Kremens B, Hero B, Esser J, Weinel P, Filger-Brillinger J, Fleischhack G, Graf N, Gruttner HP, Niemeyer C, Schulz A, Wickmann L, Berthold F. Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma. Cancer Immunol Immunother. 2002 Apr;51(2):107-10. Epub 2002 Feb 01.

Other Publications:

Krams M, Hero B, Berthold F, Parwaresch R, Harms D, Rudolph P. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification. Cancer. 2002 Feb 1;94(3):854-61.

Simon T, Hero B, Dupuis W, Selle B, Berthold F. The incidence of hearing impairment after successful treatment of neuroblastoma. Klin Padiatr. 2002 Jul-Aug;214(4):149-52.

Spitz R, Hero B, Westermann F, Ernestus K, Schwab M, Berthold F. Fluorescence in situ hybridization analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations. Genes Chromosomes Cancer. 2002 Jul;34(3):299-305.

Hero B, Simon T, Spitz R, Ernestus K, Gnekow AK, Scheel-Walter HG, Schwabe D, Schilling FH, Benz-Bohm G, Berthold F. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol. 2008 Mar 20;26(9):1504-10.

Simon T, Hero B, Benz-Bohm G, von Schweinitz D, Berthold F. Review of image defined risk factors in localized neuroblastoma patients: Results of the GPOH NB97 trial. Pediatr Blood Cancer. 2008 May;50(5):965-9.

Berthold F, Hero B, Kremens B, Handgretinger R, Henze G, Schilling FH, Schrappe M, Simon T, Spix C. Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer Lett. 2003 Jul 18;197(1-2):11-7.

Spitz R, Hero B, Ernestus K, Berthold F. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma. Clin Cancer Res. 2003 Jan;9(1):52-8.

Spitz R, Hero B, Ernestus K, Berthold F. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma. Med Pediatr Oncol. 2003 Jul;41(1):30-5.

Spitz R, Hero B, Ernestus K, Berthold F. Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma. Clin Cancer Res. 2003 Oct 15;9(13):4835-40.

von Schweinitz D, Hero B, Berthold F. The impact of surgical radicality on outcome in childhood neuroblastoma. Eur J Pediatr Surg. 2002 Dec;12(6):402-9.

Study ID Numbers:	CDR0000068664, GPOH-GERMANY-NB97, EU-20102, GER-GPOH-NB97
First Received:	June 6, 2001
Last Updated:	August 23, 2008
ClinicalTrials.gov Identifier:	NCT00017225
Health Authority:	United States: Federal Government

Keywords provided by National Cancer Institute (NCI):

localized resectable neuroblastoma

regional neuroblastoma

disseminated neuroblastoma

stage 4S neuroblastoma

recurrent neuroblastoma

localized unresectable neuroblastoma

Study placed in the following topic categories:

Melphalan

Dacarbazine

Neuroectodermal Tumors, Primitive

Vindesine

Vincristine

Carboplatin

Cyclophosphamide

Etoposide phosphate

Neuroblastoma

Recurrence

Doxorubicin

Neuroectodermal Tumors

Ifosfamide

Cisplatin

Neoplasms, Germ Cell and Embryonal

Tretinoin

Neuroepithelioma

Etoposide

Neuroectodermal Tumors, Primitive, Peripheral

Neoplasms, Glandular and Epithelial

Isophosphamide mustard

Additional relevant MeSH terms:

Neoplasms by Histologic Type

Immunologic Factors

Molecular Mechanisms of Pharmacological Action

Antineoplastic Agents

Mitosis Modulators

Neoplasms, Nerve Tissue

Physiological Effects of Drugs

Antimitotic Agents

Antibiotics, Antineoplastic

Immunosuppressive Agents

Pharmacologic Actions

Neoplasms

Therapeutic Uses

Tubulin Modulators

Myeloablative Agonists

Antineoplastic Agents, Alkylating

Neoplasms, Neuroepithelial

Antirheumatic Agents

Antineoplastic Agents, Phytogenic

Alkylating Agents

ClinicalTrials.gov processed this record on December 03, 2008

Sponsored by:	Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00017225